ClinicalTrials.Veeva

Menu

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Novartis logo

Novartis

Status and phase

Terminated
Phase 2

Conditions

Relapse Remitting Multiple Sclerosis

Treatments

Drug: VAY736
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02038049
2013-002324-16 (EudraCT Number)
CVAY736X2202

Details and patient eligibility

About

This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis (RRMS).

Full description

The study was planned to be conducted in approximately 96 patients. However, after enrolling 8 patients, the recruitment was terminated based on strategic considerations.

Enrollment

8 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key inclusion criteria:

  • Male and female patients aged 18 to 55 years.

  • Diagnosis of MS as defined by the 2010 revised McDonald criteria (Polman et al 2011).

  • A relapsing-remitting course of disease with:

    • at least 1 documented relapse during the previous 12 months (but not within 30 days prior to randomization ), or
    • a positive Gd-enhancing lesion on brain MRI scan at screening.
  • An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at screening.

  • No evidence of a relapse within 30 days prior to randomization.

Key exclusion criteria:

  • A manifestation of another type of MS other than RRMS.
  • Findings on screening or baseline brain MRI inconsistent with the diagnosis of MS.
  • History of chronic disease of the immune system other than MS, or a known immunodeficiency syndrome.
  • Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.
  • Women of child-bearing potential and Pregnant or nursing (lactating) women.
  • Screening CBC (complete blood count) laboratory values as follows:
  • Hemoglobin levels below 10.0 g/dL
  • Total leukocyte count less than 3,000 cells/µL
  • Neutropenia, defined as absolute neutrophil counts less than 1500 cells/mm3
  • Platelets less than 100,000/µL

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

8 participants in 2 patient groups, including a placebo group

VAY736
Experimental group
Description:
Intravenous infusion of VAY736
Treatment:
Drug: VAY736
Placebo to VAY736
Placebo Comparator group
Description:
Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
Treatment:
Drug: Placebo

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems